Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 2/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50646 | 0.81 | MAPT (0.68) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL11238566 | 0.79 | SRD5A2 (0.50) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL27722721 | 0.78 | MAPT (0.48) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL737226 | 0.78 | MAPT (0.48) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL4622020 | 0.78 | MAPT (0.48) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL2520574 | 0.78 | ALDH1A1 (0.32) | MAPTHPGDRAB9AKMT2AALDH1A1 | |
| SCHEMBL10411946 | 0.78 | ACACB (0.49) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL163209 | 0.78 | ALDH1A1 (0.72) | MAPTHPGDLMNARAB9AL3MBTL1 | |
| SCHEMBL536808 | 0.77 | TSHR (0.63) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5808115 | 0.77 | CA1 (0.38) | MAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164996-A | Sesquiterpene lactone scaberol C selenoether derivative, preparation method and application thereof | 沈阳药科大学 | 2024-06-11 | — | — | CN | claimed |
| CN-118164997-A | Sesquiterpene lactone scaberol C thioether derivative, and preparation method and application thereof | 沈阳药科大学 | 2024-06-11 | — | — | CN | claimed |
| CN-118164998-A | Sesquiterpene lactone scaberol C dithio carbamate derivative and preparation method and application thereof | 沈阳药科大学 | 2024-06-11 | — | — | CN | claimed |
| CN-111153910-B | Elephantopus scaber seed lactone derivative and preparation method and application thereof | 沈阳药科大学 | 2021-07-30 | — | — | CN | claimed |
| CN-111153910-A | Elephantopus scaber seed lactone derivative and preparation method and application thereof | 沈阳药科大学 | 2020-05-15 | — | — | CN | claimed |
| EP-1369424-B1 | Method for purifying protected 2'-deoxycytidines | MITSUI CHEMICALS INC (JP) | 2007-08-15 | — | — | EP | claimed |
| EP-1001943-B1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-12-17 | — | — | EP | claimed |
| US-6468713-B1 | FILTER FOR PLASMA DISPLAY, A SECRET INK; PHTHALOCYANINE COMPOUND HAVING AN ACYL OR AROYL GROUP INTRODUCED ONTO THE NITROGEN ATOM ON EACH BENZOTHIAZINE RING OF THE PHTHALOCYANINE NUCLEUS; REACTION WITH ANHYDRIDE | YAMAMOTO CHEMICALS, INC. (JP) | 2002-10-22 | — | — | US | claimed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | claimed |
| US-6072060-A | Synthesis of taxol, taxol analogs and their intermediates with variable A-ring side chain structures and compositions thereof | BRYN MAWR COLLEGE (US) | 2000-06-06 | — | — | US | claimed |
| EP-1001943-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-05-24 | — | — | EP | claimed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | claimed |
| EP-0692982-A4 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | DU PONT MERCK PHARMA (US) | 1998-03-11 | — | — | EP | claimed |
| EP-0639559-B1 | Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines | ROHM & HAAS (US) | 1997-10-15 | — | — | EP | claimed |
| JP-H08509710-A | — | — | 1996-10-15 | — | — | JP | claimed |
| EP-0692982-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-24 | — | — | EP | claimed |
| WO-1994022494-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | claimed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | claimed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
| CN-118164997-A | Sesquiterpene lactone scaberol C thioether derivative, and preparation method and application thereof | 沈阳药科大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-118164996-A | Sesquiterpene lactone scaberol C selenoether derivative, preparation method and application thereof | 沈阳药科大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-118164998-A | Sesquiterpene lactone scaberol C dithio carbamate derivative and preparation method and application thereof | 沈阳药科大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-114042171-A | Bacterial imaging agents and methods of use thereof | 文森医学公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20220023277-A1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL, INC. | 2022-01-27 | — | — | US | disclosed |
| CN-111153910-B | Elephantopus scaber seed lactone derivative and preparation method and application thereof | 沈阳药科大学 | 2021-07-30 | — | — | CN | disclosed |
| US-11059802-B2 | Carbonic anhydrase targeting agents and methods of using same | VISEN MEDICAL, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3673922-A1 | INTEGRIN TARGETING AGENTS AND METHODS OF USING SAME | VisEn Medical, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| CN-111153910-A | Elephantopus scaber seed lactone derivative and preparation method and application thereof | 沈阳药科大学 | 2020-05-15 | — | — | CN | disclosed |
| EP-2268317-B1 | INTEGRIN TARGETING AGENTS AND IN VIVO AND IN VITRO IMAGING METHODS USING THE SAME | VISEN MEDICAL INC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-2707102-B1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20190300501-A1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL, INC. | 2019-10-03 | — | — | US | disclosed |
| EP-2831264-B1 | BACTERIAL IMAGING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL INC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10221159-B2 | Carbonic anhydrase targeting agents and methods of using same | VISEN MEDICAL, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2885006-B1 | PROSTATE SPECIFIC ANTIGEN AGENTS AND METHODS OF USING SAME FOR PROSTATE CANCER IMAGING | VISEN MEDICAL INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9999687-B2 | Fluorescent imaging agents | VISEN MEDICAL, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3320923-A1 | FLUORESCENT IMAGING AGENTS | Visen Medical, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2732826-B1 | Fluorescent imaging agents | VISEN MEDICAL INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9694089-B2 | Integrin targeting agents and in-vivo and in-vitro imaging methods using the same | VISEN MEDICAL, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170119908-A1 | Fluorescent Imaging Agents | VISEN MEDICAL, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9427481-B2 | Fluorescent imaging agents | VISEN MEDICAL, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9375493-B2 | Bacterial imaging agents and methods of using same | VISEN MEDICAL, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9371362-B2 | Prostate specific antigen agents and methods of using same for prostate cancer imaging | VISEN MEDICAL, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2885006-A1 | PROSTATE SPECIFIC ANTIGEN AGENTS AND METHODS OF USING SAME FOR PROSTATE CANCER IMAGING | VisEn Medical, Inc. (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2244741-B1 | FLUORESCENT IMAGING AGENTS | VISEN MEDICAL INC (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2831264-A1 | BACTERIAL IMAGING AGENTS AND METHODS OF USING SAME | VisEn Medical, Inc. (US) | 2015-02-04 | — | — | EP | disclosed |
| US-8815214-B2 | Fluorescent imaging agents | VISEN MEDICAL, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140170066-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | MERCK & CO., INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2732826-A1 | Fluorescent imaging agents | Visen Medical, Inc. (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20140113322-A1 | SUPRAMOLECULAR NANOBEACON IMAGING AGENTS AS PROTEASE SENSORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-04-24 | — | — | US | disclosed |
| EP-2707102-A2 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | Visen Medical, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20140050662-A1 | PROSTATE SPECIFIC ANTIGEN AGENTS AND METHODS OF USING SAME FOR PROSTATE CANCER IMAGING | VISEN MEDICAL, INC. | 2014-02-20 | — | — | US | disclosed |
| WO-2014028057-A1 | PROSTATE SPECIFIC ANTIGEN AGENTS AND METHODS OF USING SAME FOR PROSTATE CANCER IMAGING | VISEN MEDICAL, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-20130309168-A1 | BACTERIAL IMAGING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2013148319-A1 | BACTERIAL IMAGING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120321563-A1 | Carbonic Anhydrase Targeting Agents and Methods of Using Same | VISEN MEDICAL, INC. | 2012-12-20 | — | — | US | disclosed |
| WO-2012154885-A2 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20110165075-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | MERCK SHARP & DOHME CORP. | 2011-07-07 | — | — | US | disclosed |
| EP-2268317-A2 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | Visen Medical, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| WO-2009114776-A2 | INTEGRIN TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090220430-A1 | Fluorescent Imaging Agents | VISEN MEDICAL, INC. | 2009-09-03 | — | — | US | disclosed |
| EP-1253154-B1 | Method for purifying 5'-protected 2'-deoxypurine nucleosides | MITSUI CHEMICALS INC (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| EP-1369424-B1 | Method for purifying protected 2'-deoxycytidines | MITSUI CHEMICALS INC (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1233013-B1 | NOVEL PHENYLALANINE DERIVATIVES | AJINOMOTO KK (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7160874-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-7074917-B2 | Method for purifying 5′ -protected 2′ -deoxypurine nucleosides | MITSUI CHEMICALS, INC. (JP) | 2006-07-11 | — | — | US | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| US-20060009635-A1 | Method for purifying 5' -protected 2' -deoxypurine nucleosides | MITSUI CHEMICALS, INC. (JP) | 2006-01-12 | — | — | US | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| US-6958391-B2 | Method for purifying 5′-protected 2′-deoxypurine nucleosides | MITSUI CHEMICALS, INC. (JP) | 2005-10-25 | — | — | US | disclosed |
| EP-1585515-A2 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-6936709-B2 | Method for purifying protected 2′-deoxycytidines and hydrated crystals thereof | MITSUI CHEMICALS, INC. (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | AJINOMOTO CO., INC. (JP) | 2005-03-31 | — | — | US | disclosed |
| US-6855706-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| WO-2004054973-A2 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | NOVO NORDISK A/S (DK) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
| EP-0856007-B1 | CYCLOPEPTIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-04-21 | — | — | EP | disclosed |
| EP-1001943-B1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-12-17 | — | — | EP | disclosed |
| US-20030229223-A1 | Method for purifying protected 2'-deoxycytidines and hydrated crystals thereof | MITSUI CHEMICALS, INC. (JP) | 2003-12-11 | — | — | US | disclosed |
| EP-1369424-A1 | Method for purifying protected 2'-deoxycytidines | Mitsui Chemicals, Inc. (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-0682660-B1 | SYNTHESIS OF TAXOL, ANALOGS AND INTERMEDIATES WITH VARIABLE A-RING SIDE CHAINS | BRYN MAWR COLLEGE (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030152512-A1 | Imaging thrombus with glycoprotein llb/llla antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-08-14 | — | — | US | disclosed |
| US-6566491-B2 | Used as integrin inhibitors, in particular for the prevention and treatment of circulatory diseases, thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, angiogenic diseases and in tumor therapy. | MERCK PATENT GESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-6509484-B2 | Trifluoroacetic acid amine salt taxane derivatives useful for taxol production | NAPRO BIOTHERAPEUTICS, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20030009028-A1 | Method for purifying 5' -protected 2' -deoxypurine nucleosides | MITSUI CHEMICALS, INC. (JP) | 2003-01-09 | — | — | US | disclosed |
| EP-1260507-A1 | Synthesis of taxol, analogs and intermediates with variable A-nng side chains | BRYN MAWR COLLEGE (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1253154-A1 | Method for purifying 5'-protected 2'-deoxypurine nucleosides | Mitsui Chemicals, Inc. (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-6468713-B1 | FILTER FOR PLASMA DISPLAY, A SECRET INK; PHTHALOCYANINE COMPOUND HAVING AN ACYL OR AROYL GROUP INTRODUCED ONTO THE NITROGEN ATOM ON EACH BENZOTHIAZINE RING OF THE PHTHALOCYANINE NUCLEUS; REACTION WITH ANHYDRIDE | YAMAMOTO CHEMICALS, INC. (JP) | 2002-10-22 | — | — | US | disclosed |
| EP-1233013-A1 | NOVEL PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-08-21 | — | — | EP | disclosed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | disclosed |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | BIOMET DEUTSCHLAND GMBH (DE) | 2002-03-14 | — | — | US | disclosed |
| EP-1152035-A1 | PREFORM FOR HOLLOW MOLDING MADE OF POLYESTER RESIN COMPOSITION, HOLLOW MOLDING MADE OF POLYESTER RESIN COMPOSITION, AND PROCESS FOR PRODUCING THE SAME | Mitsui Chemicals, Inc. (JP) | 2001-11-07 | — | — | EP | disclosed |
| US-6307088-B1 | O-HYDROCARBYL N-(1-SUBSTITUTED-2-ALKOXYCARBONYL-2-(OPTIONALLY PROTECTED HYDROXY)ETHYL)CARBAMATE | NAPRO BIOTHERAPEUTICS, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-0887350-B1 | Chromene derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2001-08-22 | — | — | EP | disclosed |
| US-6262281-B1 | ANTICANCER AGENT | BRYN MAWR COLLEGE | 2001-07-17 | — | — | US | disclosed |
| EP-1085057-A1 | PHTHALOCYANINE COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND NEAR INFRARED ABSORBENT COMPRISING THE SAME | Yamamoto Chemicals, Inc. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0767221-B1 | Near infrared ray absorbing compound having high durability and its use | MITSUI CHEMICALS INC (JP) | 2000-07-05 | — | — | EP | disclosed |
| EP-0692982-B1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | DU PONT PHARM CO (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-1001943-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-05-24 | — | — | EP | disclosed |
| EP-0995761-A2 | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | Dupont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6022523-A | NOVEL CYCLIC COMPOUNDS CONTAINING CARBOCYCLIC AND HETEROCYCLIC RING SYSTEMS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-08 | — | — | US | disclosed |
| US-5888970-A | DIAGNOSIS OF ARTERIAL AND VENOUS THROMBOSIS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-30 | — | — | US | disclosed |
| US-5879657-A | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1999-03-09 | — | — | US | disclosed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | disclosed |
| EP-0887350-A1 | Chromene derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-12-30 | — | — | EP | disclosed |
| EP-0856007-A1 | CYCLOPEPTIDE DERIVATIVES | MERCK PATENT GmbH (DE) | 1998-08-05 | — | — | EP | disclosed |
| US-5788914-A | Near infrared ray absorbing compound having high durability and its use | MITSUI CHEMICALS, INC. (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0692982-A4 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | DU PONT MERCK PHARMA (US) | 1998-03-11 | — | — | EP | disclosed |
| US-5691329-A | Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| US-5635477-A | CYCLIC TETRAPEPTIDE DERIVATIVE FUSED TO A BENZENE RING; ANTICOAGULANTS; THROMBOLYTICS; CLOT LYSIS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| WO-1997014716-A1 | CYCLOPEPTIDE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-04-24 | — | — | WO | disclosed |
| EP-0767221-A1 | Near infrared ray absorbing compound having high durability and its use | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1997-04-09 | — | — | EP | disclosed |
| US-5563158-A | CARDIOVASCULAR DISORDERS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0692982-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0691987-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-17 | — | — | EP | disclosed |
| WO-1995023811-A1 | NOVEL CARBOCYCLIC COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION BY INTERACTION WITH THE GPIIB/IIIA RECEPTOR COMPLEX | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995018111-A1 | COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| US-5429918-A | Antifading agent | FUJI PHOTO FILM CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| CN-1102829-A | Synthesis of taxol, taxol analogs and intermediates thereof and compositions thereof | BRYN MAWR COLLEGE (US) | 1995-05-24 | — | — | CN | disclosed |
| WO-1994022494-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022910-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | disclosed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | disclosed |
| EP-0343307-A1 | 4-Piperidinealkanamine derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (ES) | 1989-11-29 | — | — | EP | disclosed |
| US-3931142-A | Heterocyclic containing disazo compounds | CIBA-GEIGY AG (CH) | 1976-01-06 | — | — | US | disclosed |
| US-3931142-A | Heterocyclic containing disazo compounds | CIBA-GEIGY AG (CH) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (21 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030009028-A1 | Method for purifying 5' -protected 2' -deoxypurine nucleosides | PNP, UMPS, NT5C3B | MAPT 1283/4885HPGD 1782/4885LMNA 2643/4885 |
| US-20030229223-A1 | Method for purifying protected 2'-deoxycytidines and hydrated crystals thereof | RNGTT, NSUN2, TRDMT1 | MAPT 3281/4885HPGD 4697/4885LMNA 463/4885 |
| US-20060009635-A1 | Method for purifying 5' -protected 2' -deoxypurine nucleosides | PNP, UMPS, NUDT1 | MAPT 1574/4885HPGD 2126/4885LMNA 2813/4885 |
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | MAPT 4112/4885HPGD 2146/4885LMNA 3740/4885 |
| US-20170119908-A1 | Fluorescent Imaging Agents | DNPEP, FURIN, MME | MAPT 2327/4885HPGD 1877/4885LMNA 884/4885 |
| US-20110165075-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | ITGB3, ITGAV, ITGB1 | MAPT 2616/4885HPGD 3678/4885LMNA 1893/4885 |
| US-20120321563-A1 | Carbonic Anhydrase Targeting Agents and Methods of Using Same | CA4, CA12, CA9 | MAPT 3409/4885HPGD 1240/4885LMNA 4127/4885 |
| US-20140050662-A1 | PROSTATE SPECIFIC ANTIGEN AGENTS AND METHODS OF USING SAME FOR PROSTATE CANCER IMAGING | KLK3, FOLH1, SPAG5 | MAPT 2229/4885HPGD 2290/4885LMNA 4471/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | MAPT 4773/4885HPGD 2322/4885LMNA 4860/4885 |
| US-20130309168-A1 | BACTERIAL IMAGING AGENTS AND METHODS OF USING SAME | ANTXR2, ELANE, CD68 | MAPT 3020/4885HPGD 3270/4885LMNA 3986/4885 |
| US-10221159-B2 | Carbonic anhydrase targeting agents and methods of using same | CA4, CA12, CA9 | MAPT 3409/4885HPGD 1240/4885LMNA 4127/4885 |
| US-20190300501-A1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | CA4, CA12, CA9 | MAPT 3409/4885HPGD 1240/4885LMNA 4127/4885 |
| US-20090220430-A1 | Fluorescent Imaging Agents | DNPEP, FURIN, MME | MAPT 2327/4885HPGD 1877/4885LMNA 884/4885 |
| US-11059802-B2 | Carbonic anhydrase targeting agents and methods of using same | CA4, CA12, CA9 | MAPT 3409/4885HPGD 1240/4885LMNA 4127/4885 |
| US-20050070485-A1 | Antagonistic activity to alpha 4 integrin; treating asthma, rheumatoid arthritis; N-[1-N,N-dimethylaminocarbonylcyclopropane-1-ylcarbonyl]-4-({[5-chloro-2-(methylthio)pyrimidine-4-yl]carbonyl}-amino)-L-phenylalanine | ITGB4, ITGA4, ITGAL | MAPT 4025/4885HPGD 3057/4885LMNA 2862/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | MAPT 4773/4885HPGD 2322/4885LMNA 4860/4885 |
| US-20140170066-A1 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME | ITGB3, ITGAV, ITGB1 | MAPT 2616/4885HPGD 3678/4885LMNA 1893/4885 |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | MAPT 4536/4885HPGD 39/4885LMNA 3152/4885 |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | CORO1C, CYCS, CORO1A | MAPT 4254/4885HPGD 212/4885LMNA 1733/4885 |
| US-20030152512-A1 | Imaging thrombus with glycoprotein llb/llla antagonists | FGB, SELPLG, SELL | MAPT 4542/4885HPGD 2708/4885LMNA 1619/4885 |
| US-20220023277-A1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | CA4, CA12, CA9 | MAPT 3409/4885HPGD 1240/4885LMNA 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.